BioCentury
ARTICLE | Company News

BioLeap LLC, GlaxoSmithKline deal

September 14, 2009 7:00 AM UTC

BioLeap will use its computational fragment-based drug design technology to develop compounds against undisclosed targets for GlaxoSmithKline. Further terms were not disclosed. ...